Tutorial on statistical considerations on subgroup analysis in confirmatory clinical trials

被引:49
|
作者
Alosh, Mohamed [1 ]
Huque, Mohammad F. [2 ]
Bretz, Frank [3 ,4 ]
D'Agostino, Ralph B., Sr. [5 ]
机构
[1] US FDA, Div Biometr 3, Off Biostat, OTS,CDER, Silver Spring, MD 20993 USA
[2] US FDA, Off Biostat, OTS, CDER, Silver Spring, MD 20993 USA
[3] Novartis, Stat Methodol & Consulting, Basel, Switzerland
[4] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria
[5] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA
关键词
negative subgroup treatment effect; treatment-by-subgroup interaction; supportive subgroup findings; targeted subgroup; MULTIPLE END-POINTS; SEVERE SEPSIS; DESIGN; ENRICHMENT; ALPHA; CONSISTENCY; FRAMEWORK; EFFICACY; CANCER;
D O I
10.1002/sim.7167
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Clinical trials target patients who are expected to benefit from a new treatment under investigation. However, the magnitude of the treatment benefit, if it exists, often depends on the patient baseline characteristics. It is therefore important to investigate the consistency of the treatment effect across subgroups to ensure a proper interpretation of positive study findings in the overall population. Such assessments can provide guidance on how the treatment should be used. However, great care has to be taken when interpreting consistency results. An observed heterogeneity in treatment effect across subgroups can arise because of chance alone, whereas true heterogeneity may be difficult to detect by standard statistical tests because of their low power. This tutorial considers issues related to subgroup analyses and their impact on the interpretation of findings of completed trials that met their main objectives. In addition, we provide guidance on the design and analysis of clinical trials that account for the expected heterogeneity of treatment effects across subgroups by establishing treatment benefit in a pre-defined targeted subgroup and/or the overall population. Copyright (C) 2016 John Wiley & Sons, Ltd.
引用
收藏
页码:1334 / 1360
页数:27
相关论文
共 50 条
  • [31] Statistical and Operational Considerations for 2-Stage Adaptive Designs with Simultaneous Evaluation of Overall and Marker-Selected Populations in Oncology Confirmatory Trials
    Zhang, Weidong
    Ro, Sunhee
    Jiang, Qi
    Li, Xiaoyun
    Liu, Rong
    Lu, Chengxing 'Cindy'
    Marchenko, Olga
    Zhao, Jing
    Xu, Zhenzhen
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2022, 56 (04) : 552 - 560
  • [32] Analysis of two binomial proportions in noninferiority confirmatory trials
    Lakkis, Hassan
    Lakkis, Andrew
    PHARMACEUTICAL STATISTICS, 2024, 23 (02) : 257 - 275
  • [33] Sources of Safety Data and Statistical Strategies for Design and Analysis: Clinical Trials
    Zink, Richard C.
    Marchenko, Olga
    Sanchez-Kam, Matilde
    Ma, Haijun
    Jiang, Qi
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2018, 52 (02) : 141 - 158
  • [34] Subgroup-specific dose finding in phase I clinical trials based on time to toxicity allowing adaptive subgroup combination
    Chapple, Andrew G.
    Thall, Peter F.
    PHARMACEUTICAL STATISTICS, 2018, 17 (06) : 734 - 749
  • [35] Review of Statistical Innovations in Trials Supporting Vaccine Clinical Development
    Heyse, Joseph
    Chan, Ivan
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2016, 8 (01): : 128 - 142
  • [36] Clinical pharmacology considerations for first-in-human clinical trials for enzyme replacement therapy
    Stern, Sydney
    Wang, Jie
    Li, Ruo-Jing
    Hon, Yuen Yi
    Weis, Shawna L.
    Wang, Yow-Ming C.
    Schuck, Robert
    Pacanowski, Michael
    JOURNAL OF INHERITED METABOLIC DISEASE, 2024, 47 (05) : 1096 - 1106
  • [37] SPECIFIC STATISTICAL CONSIDERATIONS RELEVANT TO THE DESIGN AND ANALYSIS OF GINGIVITIS TRIALS DEMONSTRATING PRODUCT SUPERIORITY OR EQUIVALENCE
    KINGMAN, A
    JOURNAL OF PERIODONTAL RESEARCH, 1992, 27 (04) : 378 - 389
  • [38] Beyond exposure-response: A tutorial on statistical considerations in dose-ranging studies
    Laird, Glen
    Xu, Lei
    Liu, Meng
    Liu, Jin
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (04): : 1250 - 1258
  • [39] Recycling of Significance Levels in Testing Multiple Hypotheses of Confirmatory Clinical Trials
    Huque, Mohammad
    Mushti, Sirisha
    Alosh, Mohamed
    BIOPHARMACEUTICAL APPLIED STATISTICS SYMPOSIUM, VOL 3: PHARMACEUTICAL APPLICATIONS, 2018, : 91 - 118
  • [40] Role of clinical evaluation committees in sepsis trials: from 'valid cohort' assessment to subgroup analysis
    Jean-François Dhainaut
    Critical Care, 13